United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 – ResearchAndMarkets.com

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 – ResearchAndMarkets.com

United States INVELTYS (Loteprednol Etabonate/KPI-121) Drug Insights and Market Forecasts, 2019-2022 and 2023-2032 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “United States INVELTYS Drug Insight and Market Forecast – 2032” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about INVELTYS for acute pain in the United States. A detailed picture of the INVELTYS for acute pain in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the INVELTYS for acute pain.

The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the INVELTYS market forecast analysis for acute pain in the US, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in acute pain.

Drug Summary

INVELTYS (loteprednol etabonate/KPI-121) is a nanoparticle ocular corticosteroid formulation to treat postoperative ocular inflammation and pain. INVELTYS, as with other ophthalmic corticosteroids, are contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of ocular structures.

Dosage and Administration

Instill one to two drops of INVELTYS into the affected eye twice daily, beginning the day after surgery and continuing throughout the first 2 weeks of the postoperative period.

Mechanism of Action

Corticosteroids inhibit the inflammatory response to various inciting agents and probably delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

While glucocorticoids bind to and activate the glucocorticoid receptor, the molecular mechanisms involved in glucocorticoid/glucocorticoid receptor-dependent modulation of inflammation are not established. However, corticosteroids inhibit prostaglandin production through several independent mechanisms.

INVELTYS Analytical Perspective

In-depth INVELTYS Market Assessment

This report provides a detailed market assessment of INVELTYS for acute pain in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

INVELTYS Clinical Assessment

The report provides the clinical trials information of INVELTYS for acute pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for acute pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence INVELTYS dominance.
  • Other emerging products for acute pain are expected to give tough market competition to INVELTYS and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of INVELTYS in acute pain.
  • Our in-depth analysis of the forecasted sales data of INVELTYS from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the INVELTYS in acute pain.

Key Topics Covered:

1. Report Introduction

2. INVELTYS Overview in Acute pain

2.1. Product Detail

2.2. Clinical Development

2.2.1. Clinical studies

2.2.2. Clinical trials information

2.2.3. Safety and efficacy

2.3. Regulatory Milestone

2.4. Other Developmental Activities

2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. INVELTYS Market Assessment

5.1. Market Outlook of INVELTYS in Acute pain

5.2. The United States Analysis

5.2.1. Market Size of INVELTYS in the United States for Acute pain

6. SWOT Analysis

7. Analysts’ Views

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/myivf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.



Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900